Abstract
The new immunosuppressant FTY720 (fingolimod), an analog of the endogenous lipid sphingosine, induces transient lymphopenia through the sequestration of lymphocytes in secondary lymphoid organs. Phosphorylation of FTY720 by sphingosine kinase 2 (SphK2) yields the active metabolite FTY720-phosphate (FTY-P), which induces lymphopenia through agonism of the sphingosine 1-phosphate receptor S1P1 on endothelial cells and lymphocytes. Dephosphorylation of circulating FTY-P creates an equilibrium between FTY720 and its phosphate, and results with human patients indicate that phosphorylation of FTY720 could be rate limiting for efficacy. We report that the FTY720 derivative 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol [AAL(R)] is phosphorylated much more rapidly than FTY720 in cultured human cells and whole blood. The Kcat for AAL(R) with recombinant SphK2 is 8-fold higher than for FTY720, whereas the Km for the two substrates is very similar, indicating that the increased rate of phosphorylation results from faster turnover by SphK2 rather than a higher binding affinity. Consequently, treating cells with AAL(R), but not FTY720, triggers an apoptotic pathway that is dependent on excessive intracellular accumulation of long-chain base phosphates. In agreement with the in vitro results, phosphorylation of AAL(R) is more complete than that of FTY720 in vivo (mice), and AAL(R) is a more potent inducer of lymphopenia. These differences may be magnified in humans, because phosphorylation of FTY720 is much less efficient in humans compared with rodents. Our results suggest that AAL(R) is a better tool than FTY720 for in vivo studies with S1P analogs and would probably be a more effective immunosuppressant than FTY720.
Footnotes
This project was supported by the Cancer Institute New South Wales [Grant 08/ECF/1-03]; the Australian Research Council [Grant DP0770653]; and the National Health and Medical Research Council, Australia [Fellowship 300606]. Work at POSTECH, Korea, was supported by the BK21 program and the Korea Science and Engineering Foundation BT-Glycobiology Program [Grant 200402087].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.064873.
-
ABBREVIATIONS:
- FTY720
- fingolimod
- SphK
- sphingosine kinase
- S1P
- sphingosine 1-phosphate
- FTY-P
- FTY720-phosphate
- AAL(R)
- (R)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol
- AAL(S)
- (S)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol
- AAL-P
- phosphorylated (R)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol
- dhSph
- dihydrosphingosine
- FBS
- fetal bovine serum
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra zolium
- PI
- propidium iodide
- PCR
- polymerase chain reaction
- siRNA
- small interfering RNA
- LC
- liquid chromatography
- TLC
- thin-layer chromatography
- HMEC
- human microvascular endothelial cell.
- Received March 18, 2010.
- Accepted July 7, 2010.
- Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|